Emerging Markets Review: Rights Issues And Creeping Acquisitions In India
By Gaurav Jetley, Shamim S. Mondal Abstract We analyze the extent to which promoters of firms listed on the Bombay Stock Exchange are using rights
By Gaurav Jetley, Shamim S. Mondal Abstract We analyze the extent to which promoters of firms listed on the Bombay Stock Exchange are using rights
by Allen & Overy
When a national ‘champion’ is at stake, lively political and media debate often follows, sometimes even where the sector involved is not particularly ‘sensitive’. This is unsurprising in markets facing slow economic growth and, more recently, there has been an interesting interplay between expanding sanctions regimes and policy in this area. […] Read more
By Paul Bjacek – Accenture Contributor: Kurt Eichhorn Mergers and acquisitions in the global chemicals industry have tumbled from their highs of the 2007-2009
by A.T. Kearney
Since China first opened to the world with the 1978 economic reforms, the country’s GDP has made unprecedented progress. It is a remarkable growth story. Although there is a big gap to close to catch up with the United States, China ranked second in the world in real GDP by 2013. By 2014, 100 Chinese companies were in the Fortune 500, up from 11 in 2000 and with petrochemical firm Sinopec holding the number-three spot. […] Read more
By Jian Sun, Sherri He, Joachim von Hoyningen-Huene, Andreas Graef, Thomas Luedi, Frankie Leung, Jürgen Rothenbuecher, Bastian Sauerberg – A.T. Kearney Since China first opened to the world with the
by Baker & McKenzie
When you look at the numbers, there’s no question why global pharmaceutical companies have set their sights on emerging markets for future growth. From 2012 to 2017, global pharmaceutical sales are expected to rise 13% in the “pharmerging markets,” compared to 2% for the top mature markets, according to the IMS Institute for Healthcare Informatics. […] Read more
Pharmerging markets report By Baker & McKenzie Introduction When you look at the numbers, there’s no question why global pharmaceutical companies
By Xena Welch Guerra, Tomi Laamanen, Anna Samanta, Stefan Koller – Deloitte and University of St. Gallen Contributors: Florian Borner, Wolfgang Eckert, Kristina Faddoul, Joshua Steiner, Markus Koch, George Budden, Michael Grampp Study rationale Prevalence
By Unternehmeredition Chinas Wirtschaftswachstum verlangsamt sich weiter Chinas Bruttoinlandsprodukt (BIP) wuchs 2014 laut dem staatlichen Statistikamt um 7,4%, den niedrigsten Wert
Trainings
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
In order to become a charterholder you need to complete one of the IMAA programs